TD Cowen Issues Positive Forecast for Revvity (NYSE:RVTY) Stock Price

Revvity (NYSE:RVTY) had its target price increased by stock analysts at TD Cowen from $175.00 to $185.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen‘s price objective would indicate a potential upside of 14.46% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the company. Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Weiss Ratings upgraded shares of Revvity from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. William Blair started coverage on shares of Revvity in a research note on Monday, October 5th. They issued an “outperform” rating for the company. KeyCorp lifted their price target on shares of Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Finally, Bank of America reissued a “neutral” rating on shares of Revvity in a research note on Wednesday. Six investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $128.86.

Revvity Trading Down 1.1%

Revvity stock traded down $1.85 during mid-day trading on Wednesday, hitting $161.63. The company’s stock had a trading volume of 1,568,589 shares, compared to its average volume of 1,535,757. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The stock has a market cap of $18.04 billion, a price-to-earnings ratio of 76.93, a price-to-earnings-growth ratio of 2.76 and a beta of 1.08. The business has a 50 day moving average price of $145.89 and a 200-day moving average price of $112.62. Revvity has a 12 month low of $81.22 and a 12 month high of $171.74.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.30 by $0.08. The company had revenue of $728.90 million for the quarter, compared to the consensus estimate of $694.73 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.18 earnings per share. As a group, analysts forecast that Revvity will post 5.36 EPS for the current year.

Insider Buying and Selling at Revvity

In other Revvity news, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider owned 14,781 shares of the company’s stock, valued at approximately $2,136,297.93. The trade was a 9.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tajinder S. Vohra sold 7,330 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. This trade represents a 52.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 9,045 shares of company stock worth $1,281,439 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Revvity

A number of hedge funds and other institutional investors have recently made changes to their positions in RVTY. Ascentis Independent Advisors acquired a new stake in Revvity in the 1st quarter valued at $29,000. Pillar Financial Advisors LLC purchased a new position in shares of Revvity during the 3rd quarter worth $29,000. Heritage Family Offices LLP acquired a new position in Revvity in the third quarter valued at approximately $37,000. Global Retirement Partners LLC purchased a new position in Revvity during the second quarter worth about $51,000. Finally, Summit Securities Group LLC raised its position in Revvity by 294.6% in the first quarter. Summit Securities Group LLC now owns 663 shares of the company’s stock valued at $58,000 after purchasing an additional 495 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Key Stories Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported Q3 adjusted EPS of $1.38, above the roughly $1.30 consensus, and revenue of $728.9 million versus estimates of about $694.7 million. Revenue grew 4.3% year over year, with Life Sciences strength and margin expansion contributing to the beat. The company also raised its 2026 outlook. Q3 earnings beat and outlook
• Positive Sentiment: CFRA upgraded RVTY from Hold to Buy, adding a favorable analyst view after the results. CFRA upgrade
• Neutral Sentiment: Royal Bank of Canada raised its price target from $135 to $172 but retained a Sector Perform rating; the new target implied about 6.3% upside at the cited share price. RBC price target
• Neutral Sentiment: Some coverage questioned whether the stock is now expensive after its earnings-driven run. That concern may limit further gains, particularly given the high valuation noted in the provided market data. Dividend and valuation discussion

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.